P

PacBio

Long-read DNA sequencing systems for genomics research

Senior Specialist, Marketing Automation

Full-Time
$128.8k - $193.2k
Senior
Bachelor's
Menlo Park, CA, USA
HybridOn-site Monday through Thursday; Friday work from home.
Growth & MarketingGrowth Marketing
No H1B Sponsorship

About the job

Requirements
  • At least five years of experience with marketing automation systems.
  • Experience with business-to-business marketing strategy, especially in a complex buying cycle.
  • Basic knowledge of HTML and CSS.
  • Expertise in email best practices.
  • Experience with customer relationship management software.
  • A bachelor's degree in marketing, business, or a related discipline.
  • Current authorization to work in the United States without the need for present or future sponsorship.
  • Ability to manage multiple deadline-driven tasks simultaneously.
  • Strong analytical skills.
  • Strong attention to detail and organizational skills.
  • Interpersonal, written, and verbal communication skills.
Responsibilities
  • Own marketing campaign execution, enhance customer and prospect engagement programs, ensure the quality of campaign communications, and support the global marketing team with marketing automation.
  • Serve as the primary business owner for the marketing automation platform and guide best practices for planning, designing, and executing campaigns that reach target audiences and capture relevant data in the customer relationship management system.
  • Partner with marketing and commercial teams to launch, track, and report on digital campaigns, including email, webinars, and web landing pages.
  • Establish and measure analytics and provide updates on campaign performance.
  • Develop and optimize lead scoring, segmentation, and routing processes to improve lead qualification and timely outreach from global commercial teams.
  • Improve system processes and automation rules within the marketing automation platform and its integrations with the customer relationship management system.
  • Serve as the primary business owner for the business-to-business eCommerce store, ensuring products, pricing, and images are accurate and updated in coordination with new product introductions.
  • Develop and execute email programs for targeted audiences, including welcome, nurture, trigger, re-engagement, and retention programs.
  • Create and maintain the library of HTML templates, landing pages, and forms; manage list pulls and uploads for digital campaigns.
  • Improve e-marketing activities through A/B testing of campaign subject lines, content, and offers, and provide strategic recommendations to improve response effectiveness and efficiency.
  • Advise program owners on marketing automation capabilities, testing, and projected results; host regular sessions to update stakeholders on campaign performance and best practices.
  • Document marketing automation processes, programs, and procedures.
  • Ensure external campaign source tracking is captured and data integrity is maintained for closed-loop reporting.
  • Research marketing automation practices and recommend strategies to management for using new innovations.
  • Visit and work at company locations when required for proper performance of duties.
Desired Qualifications
  • Experience with Pardot/Account Engagement automation tools.
  • JavaScript knowledge.
  • Marketing, copywriting, or editing skills.
  • Experience with Salesforce.

About the company

PacBio designs long-read DNA sequencing systems that help researchers read complete genomes, transcriptomes, and epigenomes. Its Revio and Vega platforms use proprietary HiFi sequencing chemistry, combining the completeness of long reads with the accuracy of short reads, supported by library prep kits, reagents, and the SMRT Link software suite. Specialized tools such as Kinnex for full-length RNA sequencing and PureTarget for targeted enrichment extend the platform into human genomics, oncology, microbial, agricultural, and biopharma research. What sets PacBio apart is its focus on accuracy and completeness over raw throughput, giving scientists confidence in genomic regions that short-read technologies often miss. The goal is to enable the promise of genomics to advance human health.

Company Size

N/A

Company Stage

N/A

Total Funding

N/A

Headquarters

N/A

Founded

N/A

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 consumables rose 6% to $20.1 million as clinical shipments jumped 67%.
  • One-third of installed base opted into SPRQ-Nx by June, signaling adoption.
  • Vega SPRQ-Nx launches August 2026, expanding throughput and clinical market reach.

What critics are saying

  • Q2 2026 revenue stayed flat at $39 million; 2026 guidance fell to $155-$165 million.
  • Cash-flow breakeven slipped to 2028 after Christian Henry exited for Mark Van Oene.
  • Without SPRQ-Nx volume, PacBio burns cash, misses 2028 breakeven, and dilutes shareholders.

What makes PacBio unique

  • SPRQ-Nx on Revio cuts HiFi genome list price to $345, with multi-use SMRT Cells.
  • DNAstack and 30 institutions built a federated 10,000-plus HiFi rare-disease dataset.
  • GenomOncology integrated PacBio HiFi WGS into clinician-ready oncology reporting workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Company News

Yahoo Finance
Aug 6th, 2026
PacBio CEO steps down as revenue stalls at $39M and cash-flow breakeven pushed to 2028

Pacific Biosciences of California reported flat Q2 2026 revenue of $39 million whilst announcing a leadership change and revised outlook. CEO Christian Henry stepped down, with Mark Van Oene taking over immediately. Consumables revenue grew 6% to $20.1 million, driven by clinical customers whose shipments jumped 67% year-over-year. However, instrument revenue fell 9% to $12.8 million due to fewer Vega shipments and lower average selling prices. The company lowered its 2026 revenue forecast to $155 million–$165 million and delayed expected cash-flow breakeven to 2028. The revised outlook reflects slower adoption of its SMRT Next chemistry, which reduces sequencing costs by 30%, as customers validate the technology and work through existing reagent inventories. PacBio does not expect a significant consumables ramp until late 2026.

Associated Press
Jul 30th, 2026
GenomOncology and PacBio launch integrated long-read whole-genome sequencing workflow for oncology labs

GenomOncology, a precision oncology software company, has launched an integrated workflow for somatic whole-genome sequencing in oncology. The solution combines PacBio's HiFi WGS research-use-only secondary analysis pipeline with GenomOncology's Pathology Workbench platform to deliver standardised, clinician-ready reporting for clinical laboratories. The workflow addresses the challenge of translating long-read sequencing outputs into structured reports. It connects PacBio's pipeline, which handles analysis from raw sequencing through variant calls, with GenomOncology's platform for tertiary analysis, including quality control review, variant interpretation, and configurable report generation. A key feature is modular reporting architecture, enabling laboratories to derive tumour-specific sub-panels from shared WGS data whilst standardising upstream sequencing processes. The workflow can be deployed on-premises or on public cloud platforms. GenomOncology will present the workflow at the Cancer Genomics Consortium Annual Meeting in Houston from 1-5 August 2026.

Associated Press
May 26th, 2026
PacBio launches SPRQ-Nx chemistry enabling sub-$300 HiFi genomes with AI-enhanced sequencing

PacBio has begun worldwide shipping of its SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi sequencing platform. The technology brings the per genome list price to $345, with the possibility of sub-$300 genomes for customers sequencing at scale. The company has enhanced its AI capabilities through updates to DeepConsensus, an algorithm developed with Google, including optimisations from Google's AlphaEvolve coding agent. PacBio is also advancing deep learning models for epigenetic detection, including updated methylation models and a new 5-hydroxymethyl-cytosine caller. Beta testing across 20 sites involving over 1,400 runs showed increased yield and lower failure rates compared to previous SPRQ chemistry. The improvements are available on existing Revio systems through software upgrades, with plans to bring SPRQ-Nx chemistry to the Vega benchtop system later in 2026.

Yahoo Finance
May 12th, 2026
PacBio shares drop 14% on revenue miss despite narrower Q1 loss

Pacific Biosciences of California saw its shares fall 14.2% after reporting mixed first-quarter 2026 results. The genomics company's revenue came in at $37.18 million, missing Wall Street's expectations of $40 million by over 7% and remaining flat year-on-year. While PacBio beat earnings expectations with an adjusted loss per share of $0.12 compared to the anticipated $0.13 loss, the revenue shortfall overshadowed this positive development. The company continues to face challenges including annualised revenue decline over the past two years, negative margins and significant cash burn. PacBio shares are down 24.7% year-to-date and trading at $1.39, 48.1% below their 52-week high of $2.67 from January 2026.

Yahoo Finance
May 7th, 2026
PacBio misses Q1 revenue estimates at $37.18M, flat year-on-year despite record consumables

Pacific Biosciences of California missed Q1 CY2026 revenue expectations, reporting sales of $37.18 million versus analyst estimates of $40 million, representing a 7.1% miss and flat year-on-year performance. The genomics company's non-GAAP loss of $0.12 per share beat consensus estimates by 8.7%. CEO Christian Henry noted record consumable revenue driven by increasing clinical adoption of HiFi sequencing, but instrument revenue, particularly for Vega, fell below expectations. The company's adjusted EBITDA was -$8.17 million with a -22% margin. Despite recent struggles, with revenue declining 10.6% annually over the past two years, analysts expect 12.6% growth over the next 12 months. PacBio has a market capitalisation of $530.9 million.